These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36228400)

  • 21. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal change of sFlt-1/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction.
    Herraiz I; Quezada MS; Rodriguez-Calvo J; Gómez-Montes E; Villalaín C; Galindo A
    Ultrasound Obstet Gynecol; 2018 Nov; 52(5):631-638. PubMed ID: 28876491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of adverse perinatal outcome by serum placental growth factor and soluble fms-like tyrosine kinase-1 in women undergoing induction of labor.
    Fiolna M; Machuca M; Karampitsakos T; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Nov; 54(5):604-608. PubMed ID: 31444934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful Marker for Differential Diagnosis and Prognosis Evaluation in Chinese Women.
    Lou WZ; Jiang F; Hu J; Chen XX; Song YN; Zhou XY; Liu JT; Bian XM; Gao JS
    Dis Markers; 2019; 2019():6270187. PubMed ID: 31396294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. sFlt-1/PlGF ratio for the prediction of the time of delivery.
    Graupner O; Lobmaier SM; Ortiz JU; Karge A; Kuschel B
    Arch Gynecol Obstet; 2018 Sep; 298(3):567-577. PubMed ID: 29968165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between placental weight and angiogenic markers sFlt-1 and PlGF in women with preeclampsia and fetal growth restriction.
    Lorenz-Meyer LA; Frank L; Sroka D; Busjahn A; Henrich W; Verlohren S
    Pregnancy Hypertens; 2022 Jun; 28():149-155. PubMed ID: 35453103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. sFlt-1 to PlGF ratio cut-offs to predict adverse pregnancy outcomes in early-onset FGR and SGA: a prospective observational study.
    Bonacina E; Armengol-Alsina M; Hurtado I; Garcia-Manau P; Ferrer-Oliveras R; Monreal S; Pancorbo M; Mendoza M; Carreras E
    J Obstet Gynaecol; 2022 Oct; 42(7):2840-2845. PubMed ID: 35980876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women.
    Sovio U; Gaccioli F; Cook E; Hund M; Charnock-Jones DS; Smith GC
    Hypertension; 2017 Apr; 69(4):731-738. PubMed ID: 28167687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy.
    Birdir C; Droste L; Fox L; Frank M; Fryze J; Enekwe A; Köninger A; Kimmig R; Schmidt B; Gellhaus A
    Pregnancy Hypertens; 2018 Apr; 12():124-128. PubMed ID: 29674192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study.
    Sabriá E; Lequerica-Fernández P; Lafuente-Ganuza P; Eguia-Ángeles E; Escudero AI; Martínez-Morillo E; Barceló C; Álvarez FV
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):758-767. PubMed ID: 29498431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.
    Ren Z; Cui N; Zhu M; Khalil RA
    Am J Physiol Heart Circ Physiol; 2018 Jul; 315(1):H33-H47. PubMed ID: 29569955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management.
    Nobrega GM; Guida JP; Novaes JM; Solda LM; Pietro L; Luz AG; Lajos GJ; Ribeiro-do-Valle CC; Souza RT; Cecatti JG; Mysorekar IU; Dias TZ; Laura Costa M
    Pregnancy Hypertens; 2023 Mar; 31():32-37. PubMed ID: 36525933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased Placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) Drives the Antiangiogenic Profile of Maternal Serum Preceding Preeclampsia but Not Fetal Growth Restriction.
    Gaccioli F; Sovio U; Gong S; Cook E; Charnock-Jones DS; Smith GCS
    Hypertension; 2023 Feb; 80(2):325-334. PubMed ID: 35866422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. sFlt-1/PlGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical artery flow.
    Quezada MS; Rodríguez-Calvo J; Villalaín C; Gómez-Arriaga PI; Galindo A; Herraiz I
    Ultrasound Obstet Gynecol; 2020 Oct; 56(4):549-556. PubMed ID: 31840879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.
    Bednarek-Jędrzejek M; Kwiatkowski S; Ksel-Hryciów J; Tousty P; Nurek K; Kwiatkowska E; Cymbaluk-Płoska A; Torbé A
    J Perinat Med; 2019 Sep; 47(7):732-740. PubMed ID: 31339858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
    Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
    J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Placental Growth Factor and Soluble, Fms-Like Tyrosine Kinase-1 in Preeclampsia: A Case-Cohort (PEARL) Study.
    Fillion A; Guerby P; Lachance C; Comeau MP; Bussières MC; Doucet-Gingras FA; Zérounian S; Demers S; Laforest G; Menzies D; Bujold E
    J Obstet Gynaecol Can; 2020 Oct; 42(10):1235-1242. PubMed ID: 32718871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection.
    Giardini V; Ornaghi S; Gambacorti-Passerini C; Casati M; Carrer A; Acampora E; Vasarri MV; Arienti F; Vergani P
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.